切换至 "中华医学电子期刊资源库"
高级检索
中华诊断学电子杂志

中华诊断学电子杂志 ›› 2013, Vol. 01 ›› Issue (01) : 57 -61. doi: 10.3877/cma.j.issn.2095-655X.2013.01.12

所属专题： 文献；

临床研究

β-tubulin-Ⅲ、E-cadherin和α-catenin在乳腺癌及癌前病变中的表达及诊断意义
王刚平1,†(), 张红2, 梁云爱1, 张作峰3, 袁宗怀3, 郭小艳1   
  1. 1. 276826　日照市人民医院　济宁医学院附属日照市人民医院病理科
    2. 276826　日照市人民医院　济宁医学院附属日照市人民医院科教科
    3. 276826　日照市人民医院　济宁医学院附属日照市人民医院乳腺外科
  • 收稿日期:2013-10-06 出版日期:2013-11-26
  • 通信作者: 王刚平
  • 基金资助:
    日照市应用技术研究与开发计划项目(2060402-4); 济宁医学院2013年度科研计划重点项目(JY2013KJ051)

The expressions and diagnostic significance of β-tubulin-Ⅲ, E-cadherin and α-catenin in precancerous Lesions and carcinoma of the breast

Gangping Wang1,†(), Hong Zhang2, Yunai Liang1, Zuofeng Zhang3, Zonghuai Yuan3, Xiaoyan Guo1   

  1. 1. Department of Pathology, Rizhao People′s Hospital, Affiliated Rizhao People′s Hospital of Jining Medical College, Rizhao 276826, China
  • Received:2013-10-06 Published:2013-11-26
  • Corresponding author: Gangping Wang
  • About author:
    Corresponding author: Wang Gangping, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

王刚平, 张红, 梁云爱, 张作峰, 袁宗怀, 郭小艳. β-tubulin-Ⅲ、E-cadherin和α-catenin在乳腺癌及癌前病变中的表达及诊断意义[J]. 中华诊断学电子杂志, 2013, 01(01): 57-61.

Gangping Wang, Hong Zhang, Yunai Liang, Zuofeng Zhang, Zonghuai Yuan, Xiaoyan Guo. The expressions and diagnostic significance of β-tubulin-Ⅲ, E-cadherin and α-catenin in precancerous Lesions and carcinoma of the breast[J]. Chinese Journal of Diagnostics(Electronic Edition), 2013, 01(01): 57-61.

目的

探讨乳腺癌前病变及浸润性癌中β-tubulin-Ⅲ、E-cadherin和α-catenin的表达及诊断意义。

方法

采用免疫组织化学UltraSensitiveTM S-P法检测20例乳腺非典型导管上皮增生(ADH)、60例乳腺导管原位癌(DCIS)和90例浸润性乳腺癌(IDC)中的β-tubulin-Ⅲ、E-cadherin和α-catenin的表达，以30例正常乳腺组织作对照。

结果

β-tubulin-Ⅲ微管蛋白的表达：(1)β-tubulin-Ⅲ微管蛋白在正常对照组、ADH、DCIS和IDC组中表达率为22.0%，55.0%，71.7%，84.4%，4组间差异有统计学意义(χ2＝22.298，P<0.05)，两两组间比较，导管原位癌组、浸润性导管癌组与非典型导管增生组、正常对照组比较均差异有统计学意义(χ2＝39.525，22.474，6.551，P<0.05)。2. E-cadherin和α-catenin的表达：在正常对照组、ADH、DCIS和IDC组中，E-cadherin的表达率分别为100%、75.0%、68.3%和41.1%，α-catenin的表达率为100.0%、80.0%、73.3%和56.7%，在四组中E-cadherin和α-catenin的表达差异有统计学意义(χ2＝18.65，10.97，P<0.05)。

结论

乳腺癌前病变中β-tubulin-Ⅲ过表达，可能是乳腺癌形成的早期事件；E-cadherin和α-catenin在乳腺细胞过度增殖、恶性转化的过程中起重要作用，可作为判断组织病变程度及侵袭能力强弱的因素，β-tubulin-Ⅲ微管蛋白及E-cadherin、α-catenin有可能成为诊断和评估乳腺癌变和治疗的指标。

关键词: 乳腺肿瘤, 癌前病变, 微管蛋白, 钙黏素, 连环蛋白
Objective

To explore the expression and diagnostic significance of β-tubulin-Ⅲ proteins, E-cadherin and α-catenin in breast precancerous lesions, including atypical ductal hyperplasia (ADH), ductal carcinoma in situ (DCIS) and invasive ductal carcinomas (IDC).

Methods

The expressions of β-tubulin-Ⅲ, E-cadherin and α-catenin were investigated by immunhistochemical UltraSensitiveTM S-P method of precancerous Lesions including 20 cases of ADH, 60 cases of DCIS, and 90 cases of carcinoma of the breast. 30 cases of normal breast tissues were selected as a control group.

Results

(1)Significant differences of the β-tubulin-Ⅲ proteins expression were found among the four groups of normal breast tissues(20%), ADH(55.0%), DCIS(71.7%)and IDC(84.4%), (χ2=22.298, P<0.05), (P<0.05). (2)The expressions of E-cadherin and α-catenin in observed and controll groups: The expressions of E-cadherin in normal group, ADH, DCIS and IDC were 100%, 75.0%, 68.3% and 41.1%.The expressions of α-catenin in normal group, ADH, DCIS and IDC groups were 100%, 80.0%, 73.3% and 56.7%.There were significant differences of the expressions of E-cadherin and α-catenin between DCIS and IDC(χ2=18.650, 10.970, P<0.05).

Conclusions

Abnormal expression of β-tubulin-Ⅲ may be an early event in the development of breast tumor. The aberration of β-tubulin-Ⅲ may play a key role during oncogenesis and promote breast cellular transformation into malignancy. The abnormal expressions of E-cadherin and α-catenin with the degree of breast disease relates to the development, progression and metastasis of breast carcinoma, which may serve as one of the parameters for diagnosis of breast carcinoma and determine biological behavior and prognosis of breast carcinoma.

Key words: Breast neoplasms, Precancerous Lesions, Microtubulin, Cadherin, Catenin
表1 受检者不同乳腺组织中β-tubulin-Ⅲ蛋白的表达
组别 例数 β-tubulin-Ⅲ蛋白表达(例数) β-tubulin-Ⅲ表达阳性率(%)
－ ＋ ＋＋ ＋＋＋
正常组织 30 24 3 2 1 20.0
非典型增生 20 9 6 3 2 55.0a
导管原位癌 60 17 11 14 18 71.7a
浸润性乳腺癌 90 14 10 27 39 84.4a
χ2值 ? 22.298 ?
P值 ? <0.01 ?
图1 E-cadherin和α-catenin在不同乳腺组织中的异常表达图像
表2 受检者不同乳腺组织中E-cadherin和α-catenin的表达(例数)
组别 例数 E-cadherin表达 α-catenin表达
－ ＋ － ＋
正常组织 30 0 30 0 30
非典型增生 20 5 15 4 16
导管原位癌 60 19 41 16 44
浸润性乳腺癌 90 53 37 39 51
χ2值 ? 18.65 10.97
P值 ? <0.01 <0.01
[1]
Lakhani SR,Ellis IO,Schnitt SJ, et al.WHO classification of tumours of the breast [M]. Lyon, France: IARC Press, 2012.
[2]
Wang GP,Zhang H,Zhang ZF, et al.Clinical and pathological characteristics of intraductal proliferative lesions and coexist with invasive ductal carcinomas [J]. Chinses-German J Clin Oncol, 2013, 12(12): 574-580.
[3]
王刚平,梁云爱,张作峰, 等. CD105标记MVD及HIF-1α在乳腺癌及癌前病变中的表达及意义[J/CD]. 中华临床医师杂志(电子版), 2013, 7(16): 7386-7391.
[4]
冯俊,李建军,应荣彪, 等. βⅢ-微管蛋白在乳腺癌癌变不同阶段的表达及意义[J/CD]. 中华临床医师杂志(电子版), 2011, 5(8): 2197-2200.
[5]
李广慧．E-cadherin和α-catenin在乳腺浸润性导管癌及乳腺癌前病变中的表达及意义[D]．大连：大连医科大学.2008.
[6]
Tanaka K,Iwamoto S,Gon G, et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas[J]. Clin Cancer Res, 2000, 6(1): 127-134.
[7]
Jawhari A,Jordan S,Poole S, et al.Abnormal immuneoreactivity of the E-cadherin/ catenin complex in gastric carcinoma：relationship with patient survival[J]. Gastroenterology, 1997, 112(1): 46-54.
[8]
Kausilia K,Krishandath,Hugow, et al.Reduced expression of the cadherin complex in oesopnageal adenocarcinoma correcateswith poor prognosis[J]. J Pathol , 1997, 182: 3.
[9]
Gritsko T,Williams A,Turkson J, et al.Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells[J]. Clin Cancer Res, 2006, 12(1): 11-19.
[10]
冶俊玲,韩静绮,郭新建, 等. 食管鳞癌组织中β微管蛋白Ⅲ、Stathmin和P糖蛋白的表达与预后[J]. 世界华人消化杂志, 2012, 20(27): 2613-2617.
[11]
Kam Y,Quaranta V. Cadherin-bound β-catenin feeds into the Wnt pathway upon adherens junctions dissociation: evidence for an intersection between β-catenin pools[J]. PLoS ONE, 2009, 4(2): e4580.
[12]
Hulpiau P,Roy FV.Molecular evolution of the cadherin superfamily[J]. Znt Biochem Cell Biol, 2009, 41(2): 349-369.
[1] 郏亚平, 曾书娥. 含鳞状细胞癌成分的乳腺化生性癌的超声与病理特征分析[J]. 中华医学超声杂志（电子版）, 2023, 20(08): 844-848.
[2] 唐玮, 何融泉, 黄素宁. 深度学习在乳腺癌影像诊疗和预后预测中的应用[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 323-328.
[3] 康夏, 田浩, 钱进, 高源, 缪洪明, 齐晓伟. 骨织素抑制破骨细胞分化改善肿瘤骨转移中骨溶解的机制研究[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 329-339.
[4] 衣晓丽, 胡沙沙, 张彦. HER-2低表达对乳腺癌新辅助治疗疗效及预后的影响[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 340-346.
[5] 施杰, 李云涛, 高海燕. 腋窝淋巴结阳性Luminal A型乳腺癌患者新辅助与辅助化疗的预后及影响因素分析[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 353-361.
[6] 伍秋苑, 陈佩贤, 邓裕华, 何添成, 周丹. 肠道微生物在乳腺癌中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 362-365.
[7] 谭巧, 苏小涵, 侯令密, 黎君彦, 邓世山. 乳腺髓样癌的诊治进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 366-368.
[8] 周婉丽, 钱铮, 李喆. 槐耳在乳腺癌免疫治疗中的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 369-371.
[9] 熊倩, 罗凤. 乳腺癌患者术后康复现状与对策的研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 372-374.
[10] 杨小菁, 姜瑞瑞, 石玉香, 王静静, 李长天. 乳腺孤立性纤维性肿瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 375-377.
[11] 冯雪园, 韩萌萌, 马宁. 乳腺原发上皮样血管内皮瘤一例[J]. 中华乳腺病杂志(电子版), 2023, 17(06): 378-380.
[12] 康一坤, 袁芃. 三阴性乳腺癌分子遗传学及临床特征研究进展[J]. 中华乳腺病杂志(电子版), 2023, 17(05): 290-293.
[13] 王雪菲, 海琳悦, 李立方, 肖春花. Luminal A型乳腺癌的内分泌治疗与化疗[J]. 中华乳腺病杂志(电子版), 2023, 17(05): 294-300.
[14] 晏晴艳, 雍晓梅, 罗洪, 杜敏. 成都地区老年转移性乳腺癌的预后及生存因素研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 636-638.
[15] 李智铭, 郭晨明, 庄晓晨, 候雪琴, 高军喜. 早期乳腺癌超声造影定性及定量指标的对比研究[J]. 中华普外科手术学杂志(电子版), 2023, 17(06): 639-643.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号